BYLVAY

This brand name is authorized in Estonia, Croatia, Ireland, Israel, Lithuania, Poland, Romania

Active ingredients

The drug BYLVAY contains one active pharmaceutical ingredient (API):

1 Odevixibat UNII Q76KP2H4XW - ODEVIXIBAT SESQUIHYDRATE

Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Pharmacodynamic effects odevixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. Read about Odevixibat

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BYLVAY Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A05AX05		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1858608, 1858619, 1858620, 1858631
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9196, 9197, 9198, 9199
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093043, 1093044, 1093045, 1093046
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100457061, 100457106, 100457113, 100457120
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68642001, W68643001, W68644001